🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: GW642444 50mcg

Found 13 matching trials

A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In COPD Patients.

PHASE2

This study will involve the use of a new compound, GW642444 that is being d...

Status

Completed

Location

GSK Investigational Site

Start Date

2007-08

Trial ID

NCT00519376

Treatments Being Tested

GW642444M GW642444H placebo

A Study To Assess The Safety And Tolerability Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE2

The compound GW642444 has previously been found to be well tolerated with n...

Status

Completed

Location

GSK Investigational Site

Start Date

2006-11-03

Trial ID

NCT00372112

Treatments Being Tested

GW642444 Placebo

Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

The purpose of this study is to evaluate the 24-hour spirometry effect (FEV...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-03-18

Trial ID

NCT01323621

Treatments Being Tested

Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg Fluticasone Propionate 250mcg / salmeterol 50mcg Double-dummy placebo Salbutamol as needed

A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE2

This study will assess the safety and efficacy of 5 doses GW642444 in subje...

Status

Completed

Location

GSK Investigational Site

Start Date

2008-02

Trial ID

NCT00606684

Treatments Being Tested

GW642444 6.25 GW642444 3mcg GW642444 12.5mcg GW642444 25mcg GW642444 50mcg placebo

Corrected QT (QTc) Study With Flucticasone Furoate and GW642444

PHASE1

A randomised, placebo controlled thorough QTc study to evaluate the effect ...

Status

Completed

Location

GSK Investigational Site

Start Date

2010-06-23

Trial ID

NCT01209026

Treatments Being Tested

Fluticasone furoate (200 mcg)/GW642444 (25mcg) combination Fluticasone furoate (400 mcg)/GW642444 (50mcg) combination Placebo Inhaler Moxifloxacin 400mg Moxifloxacin placebo

A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

The Purpose of this study is to assess the efficacy and safety of three str...

Status

Completed

Location

GSK Investigational Site

Start Date

2009-09-25

Trial ID

NCT01009463

Treatments Being Tested

FF/GW642444 Inhalation Powder GW642444 Inhalation Powder

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease

PHASE3

The purpose of this study is to evaluate the 24-hour spirometry effect (FEV...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-03-18

Trial ID

NCT01323634

Treatments Being Tested

Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg Fluticasone Propionate 250mcg/ salmeterol 50mcg

A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo

PHASE3

The Purpose of this study is to evaluate the 24-hour spirometry effect Forc...

Status

Completed

Location

GSK Investigational Site

Start Date

2010-01-01

Trial ID

NCT01072149

Treatments Being Tested

Fluticasone Furoate (FF)/GW642444 Inhalation Powder placebo

A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

The Purpose of this study is to assess the efficacy and safety of three str...

Status

Completed

Location

GSK Investigational Site

Start Date

2009-09-25

Trial ID

NCT01017952

Treatments Being Tested

FF/GW642444 Inhalation Powder GW642444 Inhalation Powder

Investigation Of A New Medication (GW642444) In Asthmatic Patients

PHASE2

This study will evaluate efficacy (FEV1), safety, tolerability, pharmacodyn...

Status

Completed

Location

GSK Investigational Site

Start Date

2005-01

Trial ID

NCT00354874

Treatments Being Tested

GW642444 Placebo salmeterol 50mcg

Previous Next